Journal of the American Chemical Society · 2002 · 247 citations · 12 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructural BiologyLigand BindingLigand-based DesignMolecular DockingProtein-ligand DockingAlpha-helix MimicsHydrophobic FeaturesHydrophobic InteractionsMedicinal Chemistry ApplicationsPeptide Medicinal ChemistryPro-apoptotic ProteinsProtein-protein Interaction Inhibitor DesignRational Design
The rational design of low-molecular weight ligands that disrupt protein-protein interactions is still a challenging goal in medicinal chemistry. Our approach to this problem involves the design of molecular scaffolds that mimic the surface functionality projected along one face of an alpha-helix. Using a terphenyl scaffold, which in a staggered conformation closely reproduces the projection of functionality on the surface of an alpha-helix, we designed mimics of the pro-apoptotic alpha-helical Bak-peptide as inhibitors of the Bak/Bcl-xL interaction. This led to the development of a potent Bcl-xL antagonist (KD = 114 nM), whose binding affinity for Bcl-xL was assessed by a fluorescence polarization assay. To determine the binding site of the developed inhibitor we used docking studies and an HSQC-NMR experiment with 15N-labeled Bcl-xL protein. These studies suggest that the inhibitor is binding in the same hydrophobic cleft as the Bak- and Bad-peptides.
12
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Steven W. Muchmore, Michael Sattler, Heng Liang et al. · Nature · 1996 · 1.5K citations
A Protein-Counting Mechanism for Telomere Length Regulation in Yeast
Stéphane Marcand, Éric Gilson, David Shore · Science · 1997 · 521 citations